美通社

2024-11-13 19:29

/DISREGARD RELEASE: Alphamab Oncology/

We are advised by Alphamab Oncology that journalists and other readers should disregard the news release, A Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was Included in the Pilot Program for Optimizing the Review and Approval of Clinical Trials for Innovative Drugs, issued 13-Nov-2024 over PR Newswire.

source: Alphamab Oncology

想要獨家投資理財Tips?即Like etnet 全新Facebook專頁► 立即讚好

人氣文章
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運飾物趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

秋天養生食療

山今養生智慧

輕鬆護老